 |
N-{[(5S)-3-(3-fluoro-4-thiomorpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl}acetamide |
|---|---|
| Trade Name | |
| Orphan Indication | Tuberculosis |
| USA Market Approval | USA |
| USA Designation Date | 2011-02-04 00:00:00 |
| Sponsor | Sequella, Inc.;9610 Medical Center Drive, Suite 200;Rockville, Maryland, 20820 |
